Argenica Therapeutics (ASX:AGN) Interest Received : A$0.09 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Interest Received?

Argenica Therapeutics's Interest Received for the six months ended in Dec. 2023 was A$0.05 Mil.

Argenica Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.09 Mil.

Argenica Therapeutics Interest Received Historical Data

The historical data trend for Argenica Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Interest Received Chart

Argenica Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Interest Received

0.06

Argenica Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Received	Get a 7-Day Free Trial			-	-	0.02	0.04	0.05

Argenica Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.09 Mil.

Argenica Therapeutics Interest Received Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Interest Received provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Interest Received

Comparable Companies

Traded in Other Exchanges

N/A

Address

117 Broadway, Unit 4, Nedlands, WA, AUS, 6009

Website

https://www.argenica.com.au

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines